甲地孕酮对含顺铂方案化疗患者辅助治疗作用的临床观察

Clinical Observation of Megestrolacetate as Adjuvant Treatment in Cisplatin-Based Chemotherapy

目的探讨甲地孕酮(MA)在含顺铂方案化疗中减少消化道反应、保护骨髓以及改善患者生活质量的作用。方法将82例确诊为恶性肿瘤且应用含顺铂方案化疗的患者随机分为治疗组42例(MA加格拉司琼止吐治疗)和对照组40例(单纯格拉司琼止吐治疗),观察两组患者消化道反应、骨髓抑制及生活质量的变化。结果两组患者消化道反应、骨髓抑制及生活质量改善情况间差别均有显著性意义(P<0·05)。治疗组未见甲地孕酮所致的严重不良反应。结论接受含顺铂方案化疗的患者辅助应用甲地孕酮可减轻消化道反应、保护骨髓和提高生活质量。

Objective To investigate the effects of MA （megestrolacetate） in cisplatin - based chemotherapy for relieving gastrointestinal reactions, protecting bone marrow function and improving patient＇s quality of life （QOL）. Methods Eighty - two patients with malignant neoplasms, who treated with cisplatin - based regimen, were randomized into two groups. The 42 patients in trial group were treated with MA plus granisetron as antiemetic, the 40 patients in control group were treated with granisetron only. The changes of gastrointestinal reactions, bone marrow function and QOL of patients in each group were observed. Results Hematological toxicity and gastrointestinal reactions were lower in trial group than those in control group （ P 〈 0. 05 ） ; The QOL was improved significantly in trial group compared .to control group （ P 〈 0. 05）. In trial group, there was no severe adverse effects induced by MA. Conclusion Megestrolacetate has obvious effects in relieving gastrointestinal reactions, protecting bone marrow function and improving QOL for patients treated with cisplatin - based chemotherapy, being a good adjuvant drug in cisplatin -based chemotherapy regimens.